Viking Therapeutics, Inc.

Novo Nordisk A/S

Eli Lilly and Company

Freedom Broker has issued a trade idea on the biotech Viking Therapeutics. The company is expected to present fresh data from clinical trials of its main weight-loss drug, and historically, as Freedom Broker points out, the stock rises ahead of these events.

Freedom Broker says buy weight-loss drugmaker Viking ahead of 2H data releases

Shares of the biopharmaceutical company Viking Therapeutics surged 21% on Thursday, October 24. The gains were attributable to released financial results for the third quarter, which showed that the company had sufficient financial resources to continue clinical trials for its promising weight-loss pill. If they are successful, Viking could eventually challenge current market leaders Novo Nordisk and Eli Lilly. Recall that earlier this month, Morgan Stanley included Viking in a list of small-cap stocks with at least 50% upside.

#Viking Therapeutics: 2

Freedom Broker says buy weight-loss drugmaker Viking ahead of 2H data releases

Potential Eli Lilly and Novo Nordisk competitor surges 21% on third-quarter financials